抗病毒药物阿比朵尔与降低新冠病毒感染患者的院内死亡率有关。

Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients.

作者信息

Zeng Hesong, He Xingwei, Liu Wanjun, Kan Jing, He Liqun, Zhao Jinhe, Chen Cynthia, Zhang Junjie, Chen Shaoliang

机构信息

Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong Univerisity of Science & Technology, Wuhan 430030, China.

Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.

出版信息

Cardiol Discov. 2021 Dec 3;1(1):37-43. doi: 10.1097/CD9.0000000000000014. eCollection 2021 Mar.

DOI:10.1097/CD9.0000000000000014

PMID:34977907

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8710295/

Abstract

OBJECTIVE

Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM).

METHODS

This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5-7 days, = 788, 77.3%) and No-Abidol ( = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization.

RESULTS

Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes <0.8) and erythrocyte sending rate, lower interleukin-6, higher platelet counts and plasma IgG and oxygen saturation, and less frequent myocardial injury. The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol (hazard ratio (HR) = 2.610, 95% confident interval (CI): 1.980-3.440), all seen in severe and critical patients. After PSM, the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group (HR = 2.728, 95% CI: 1.598-4.659).

CONCLUSIONS

Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19. Further randomized study is warranted to confirm the findings from this study.

摘要

目的

2019年冠状病毒病（COVID-19）是一场全球公共卫生危机。目前尚无治疗严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的特效抗病毒药物。关于阿比多尔对住院死亡率影响的信息较少。本研究旨在评估倾向评分匹配（PSM）前后阿比多尔对COVID-19患者的治疗效果。

方法

这项回顾性队列研究分析了2019年12月22日至2020年3月13日在中国确诊的1019例COVID-19患者。患者被分为阿比多尔组（200毫克，每日三次，5 - 7天，n = 788，77.3%）和非阿比多尔组（n = 231，22.7%）。主要结局是住院期间的死亡率。

结果

1019例COVID-19患者的年龄为（60.4 ± 14.5）岁。与非阿比多尔治疗的患者相比，阿比多尔治疗的患者从症状出现到入院的时间更短，肾功能不全的发生率更低，白细胞计数（淋巴细胞<0.8）和红细胞沉降率更低，白细胞介素-6水平更低，血小板计数、血浆IgG和血氧饱和度更高，心肌损伤的发生率更低。PSM前，阿比多尔组的住院死亡率为17.9%，非阿比多尔组为34.6%（风险比（HR）= 2.610，95%置信区间（CI）：1.980 - 3.440），均见于重症和危重症患者。PSM后，阿比多尔组的院内死亡率为13.6%，非阿比多尔组为28.6%（HR = 2.728，95% CI：1.598 - 4.659）。